Cargando…

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib

Rheumatoid arthritis belongs to the group of chronic systemic autoimmune diseases characterized by the development of destructive synovitis and extra-articular manifestations. Cytokines regulate a wide range of inflammatory processes involved in the pathogenesis of rheumatoid arthritis and contribut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondratyev, Maxim, Rudnev, Vladimir R., Nikolsky, Kirill S., Stepanov, Alexander A., Petrovsky, Denis V., Kulikova, Liudmila I., Kopylov, Arthur T., Malsagova, Kristina A., Kaysheva, Anna L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504736/ https://www.ncbi.nlm.nih.gov/pubmed/36142375 http://dx.doi.org/10.3390/ijms231810466

Ejemplares similares

In Silico Study of the Interactions of Anle138b Isomer, an Inhibitor of Amyloid Aggregation, with Partner Proteins
por: Kondratyev, Maxim S., et al.
Publicado: (2022)

PSSNet—An Accurate Super-Secondary Structure for Protein Segmentation
por: Petrovsky, Denis V., et al.
Publicado: (2022)

Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family
por: Taldaev, Amir, et al.
Publicado: (2021)

3β-Corner Stability by Comparative Molecular Dynamics Simulations
por: Rudnev, Vladimir R., et al.
Publicado: (2022)

Current Approaches in Supersecondary Structures Investigation
por: Rudnev, Vladimir R., et al.
Publicado: (2021)

Managing of Unassigned Mass Spectrometric Data by Neural Network for Cancer Phenotypes Classification
por: Petrovsky, Denis V., et al.
Publicado: (2021)

Super Secondary Structures of Proteins with Post-Translational Modifications in Colon Cancer
por: Tikhonov, Dmitry, et al.
Publicado: (2020)

SAFoldNet: A Novel Tool for Discovering and Aligning Three-Dimensional Protein Structures Based on a Neural Network
por: Petrovskiy, Denis V., et al.
Publicado: (2023)

Modeling Side Chains in the Three-Dimensional Structure of Proteins for Post-Translational Modifications
por: Petrovskiy, Denis V., et al.
Publicado: (2023)

Molecular Dynamics Study of Citrullinated Proteins Associated with the Development of Rheumatoid Arthritis
por: Taldaev, Amir, et al.
Publicado: (2022)

Analysis of Structural Changes in the Protein near the Phosphorylation Site
por: Nikolsky, Kirill S., et al.
Publicado: (2023)

Tracking Health, Performance and Recovery in Athletes Using Machine Learning
por: Petrovsky, Denis V., et al.
Publicado: (2022)

Changes in Protein Structural Motifs upon Post-Translational Modification in Kidney Cancer
por: Tikhonov, Dmitry, et al.
Publicado: (2021)

Proteomic and molecular dynamic investigations of PTM-induced structural fluctuations in breast and ovarian cancer
por: Tikhonov, Dmitry, et al.
Publicado: (2021)

Molecular Portrait of an Athlete
por: Malsagova, Kristina A., et al.
Publicado: (2021)

Diversity of Plant Sterols Metabolism: The Impact on Human Health, Sport, and Accumulation of Contaminating Sterols
por: Kopylov, Arthur T., et al.
Publicado: (2021)

Determination of Heterogeneous Proteomic and Metabolomic Response in anti-TNF and anti-IL-6 Treatment of Patients with Rheumatoid Arthritis
por: Stepanov, Alexander A., et al.
Publicado: (2023)

Mass Spectrometric Identification of Proteins Enhanced by the Atomic Force Microscopy Immobilization Surface
por: Kaysheva, Anna L., et al.
Publicado: (2021)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Dried Blood Spot in Laboratory: Directions and Prospects
por: Malsagova, Kristina, et al.
Publicado: (2020)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Biobanks—A Platform for Scientific and Biomedical Research
por: Malsagova, Kristina, et al.
Publicado: (2020)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Tear Proteome Revealed Association of S100A Family Proteins and Mesothelin with Thrombosis in Elderly Patients with Retinal Vein Occlusion
por: Stepanov, Alexander, et al.
Publicado: (2022)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

Chromatomass-Spectrometric Method for the Quantitative Determination of Amino- and Carboxylic Acids in Biological Samples
por: Kaysheva, Anna L., et al.
Publicado: (2022)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis
por: Overstreet, A.M., et al.
Publicado: (2018)

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
por: FAN, Birao, et al.
Publicado: (2022)

Molecular Profiling of Athletes Performing High-Intensity Exercises in Extreme Environments
por: Malsagova, Kristina A., et al.
Publicado: (2023)

Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia
por: Kopylov, Arthur T., et al.
Publicado: (2023)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8psmqeoclotkn6ethk5i2ic24j